The Adderall shortage that's been going on for the last three-plus years is not caused by telehealth mills, not caused by hoarding anxious parents, not…
Sections
The Adderall shortage that’s been going on for the last three-plus years is not caused by telehealth mills, not caused by hoarding anxious parents, not caused by manufacturing problems at any one company, and not caused by an explosion of fake ADHD diagnoses, even though every one of those theories has been making the rounds for the last few years and a couple of them have been adopted as official explanations by people who should know better. It’s caused by the DEA setting an annual production quota that is smaller than the actual prescribed demand for legal stimulants, which is the kind of math problem you’d solve in middle school if it weren’t filed under “public policy” and therefore allowed to stay broken for years on end. Everything else flows from that one number being set too low.
Stimulant production in the United States is capped by the DEA every year. They set a number, the manufacturers can’t legally make more than that number, the pharmacies can only fill what’s been made, so if prescribed demand exceeds the cap you get a shortage by definition. Prescribed demand has exceeded the cap for years running, which is why the shortage hasn’t gone away, and which is why the periodic announcements that the shortage is “easing” never actually translate into your pharmacy having your medication on the day you need it. Pharmacists know this. Patients keep finding out the hard way.
The 2026 quota bump
The DEA bumped the 2026 amphetamine quota by about eight percent. Press coverage treated this like a policy win. It’s a gesture. Prescribed demand has been growing at fifty percent or higher per year in the adult ADHD segment, eight percent does not close that gap, it narrows it slightly and slowly, which is not the same thing as fixing the underlying problem. Math is unforgiving that way.
If your pharmacist tells you the shortage is over because of the bump, your pharmacist is repeating the press release, and six months from now you’ll still be calling around to seven pharmacies to find your refill. The reason is arithmetic, not pharmacy management, not insurance, not your prescriber being lazy about sending the eRx. The number was set too low again, just slightly less too low than last year.
Why the DEA sets the quota where it does
The DEA’s stated reasoning involves diversion prevention and public health, by which they mean concern that more legal supply will end up sold on the black market. The Controlled Substances Act of 1971 (the original federal scheduling law and most of the structure under which controlled medications are regulated today) requires the DEA to produce an annual estimate of legitimate medical need and to set quotas accordingly. Their estimate has lagged actual prescribed demand for several years running. Partly the methodology is conservative. Partly the agency’s institutional incentive is to err on the low side, because the political downside of being blamed for diversion has historically been higher than the downside of being blamed for shortages affecting millions of patients with prescriptions, which is the kind of asymmetry you only get to keep when the people most hurt by it aren’t politically organized.
Meanwhile the legitimate medical need has actually gone up because the field has gotten better at recognizing adult ADHD, particularly in adults who weren’t caught as kids. The diagnostic criteria didn’t change, the cultural recognition did. A lot of guys in their thirties and forties are getting evaluated now, qualifying, and being prescribed, and that population is real. Telehealth made the evaluation accessible. Some of that uptick is over-diagnosis, sure, the way some of every diagnostic uptick is, every popular diagnosis gets a fashion cycle and ADHD is in one right now. Most of it is catching up, not making up.
The telehealth scapegoat
You’ll hear a lot of blaming of telehealth platforms. Cerebral and Done got the worst of it. Some of the criticism is fair, their evaluation processes were in fact garbage. Most of it is misdirected, because even if every telehealth mill closed tomorrow, the underlying mismatch between quota and prescribed demand wouldn’t change much, since most stimulant prescribing happens in regular clinics and primary care offices and not in fly-by-night telehealth shops. The DOJ and DEA have been actively investigating telehealth prescribers for years now, which comes from the political pressure to find a villain that isn’t “the quota system is broken.” Easier to indict a few CEOs than to redo the structure that’s been failing patients since well before any of those CEOs got into the business.
What this looks like for the patient
You call your pharmacy, they don’t have it. Call three more, they don’t have it either. Drive to the one that does, they’re out of your specific strength but they have the wrong one. You go home with the wrong strength and try to make it work, or you go without for a week, or you skip the work day to call ten more pharmacies. This is happening to a lot of people every week in the US, and the literature on it is pretty clear that the experience makes ADHD treatment outcomes worse, increases dose-stacking when supply finally appears, and pushes some non-trivial number of patients toward illicit sources, which is the exact thing the quota was supposedly designed to prevent. If you’ve been blaming yourself, your prescriber, your pharmacy, or your insurance, you’ve been pointing at the wrong things. The problem is upstream of all of them, and the upstream isn’t fixing it on any timeline that helps you this month.
If your pharmacist tells you the shortage is over because of the bump, your pharmacist is repeating the press release, the math hasn’t changed, and the math is the only thing that actually matters.
What actually fixes it
The DEA could set the quota to actually match demand. That’s the answer and it isn’t complicated. The reason it doesn’t happen is institutional inertia plus a policy framework from 1971 that didn’t anticipate either telehealth or modern adult ADHD diagnosis, plus a political environment in which any move that increases stimulant supply gets attacked as “feeding the addiction crisis,” even though the actual addiction crisis is fentanyl and not Adderall, and the conflation is journalistic laziness that nobody important has bothered to push back on hard enough.
The cleaner long-term fix would be moving stimulants to Schedule III, which is a different category in the controlled-substance scheduling system that doesn’t have annual production quotas attached. Schedule III drugs include things like ketamine, anabolic steroids, and Tylenol with codeine, which is to say drugs the federal government has decided are real medications worth regulating but doesn’t need to cap the production of at a national level. Moving stimulants there would eliminate this whole category of shortage by removing the cap that creates it. The argument for the move is straightforward and the data supports it. The political appetite for it doesn’t currently exist, which means more incremental quota bumps that don’t close the gap, which means another year of the same cycle.
The kind of guy this happens to
The pattern is a guy in his thirties or forties, recently diagnosed with ADHD as an adult (often after his kid was diagnosed and he started recognizing half the symptoms in himself), got started on Vyvanse or generic Adderall, did really well on it for the first few months, work performance got measurably better, marriage was easier because he wasn’t snapping at his wife every weeknight. Then the shortage hit his pharmacy chain and the script that used to be a routine refill became a part-time job to find. Some months he gets it, some months he doesn’t, the months he doesn’t his work suffers, his sleep gets worse because he’s anxious about supply, and he gains a stress-eating fifteen pounds.
None of that is about him being a bad patient. None of it is about his prescriber being bad. It’s about the DEA setting a number too low, and the guys it’s happening to in Oregon and Washington alone are in the tens of thousands, which is the kind of number that should attract more political pressure than it has, and hasn’t, because the population most affected is also the population most embarrassed to say out loud that they need the medication.
The cardiac caveat needs saying here, because we’re talking about stimulants and the field’s been sloppy about it. Stimulants are not no-risk. The first-time-stimulant-at-fifty conversation is genuinely fraught. Anyone on multiple cardiac medications is an iffy candidate, and any prescriber who pretends stimulants are completely safe in a guy with cardiac history is a damn liar. Treatment for adult ADHD is worth doing for the right candidate. The right candidate isn’t every adult who wants better focus, and the cardiac side of the workup gets skipped at the telehealth mills the most, which is one of the ways the bad-actor model of evaluation actually harms patients beyond the diagnostic question.
What to do in the meantime
Call early. Refills should hit the pharmacy a few days before you run out, not the day of, build slack into the cycle.
Be open with your prescriber about switching strengths or formulations temporarily if your usual isn’t available. Sometimes 20mg XR is on the shelf when 30mg isn’t, and that’s worth a conversation with whoever wrote the script rather than a week without it.
Don’t stack doses when supply finally shows up to make up for the week you missed. That’s exactly how rebound and tolerance issues get worse and how the cycle gets harder to manage.
Don’t go to illicit sources because legal supply has been impossible. The counterfeit market is laced with fentanyl, including counterfeit Adderall pressed with fentanyl. People are dying from this, and the press coverage is predictably sparse because the headline doesn’t fit the dominant narrative about who’s dying of fentanyl. Slinging pills from a friend or friendly dealer isn’t worth it, just talk to your prescriber about temp adjustments. Mail-order pharmacies, which are restricted but not forbidden for controlled substances and which a fair number of psychiatrists routinely order patient stimulants from, are another option worth asking about. The logistics are mildly annoying and the supply tends to be more reliable than the big retail chains.
Why this matters beyond the shortage
The DEA quota framework was built in 1971 for a different country with a different set of stimulant indications. Adult ADHD wasn’t formally recognized in the DSM (the diagnostic manual most US clinicians use to label conditions) until 1994. The methodology the agency uses to estimate legitimate medical need was developed when the legitimate medical need was a small fraction of what it is now, and updating that methodology is institutionally hard because the agency’s incentive structure pushes toward conservative estimates that minimize political risk on the diversion side and ignore political risk on the access side. Which is the kind of asymmetric policy you get when the affected population doesn’t have a lobby.
Bottom line is this is a federal policy problem, not a medical problem and not a patient problem. The 2026 bump is real but doesn’t close the gap. Until the DEA either matches quotas to actual prescribed levels or moves stimulants to Schedule III, this is going to keep happening, the press is going to keep declaring victory every twelve months, and the guys reading this are going to keep calling seven pharmacies. Plan for that, not for the version where this gets fixed by Q3. Wait, can a clinician say in writing that the federal regulator is the one breaking this and the press is helping cover for them? Apparently yes, because pretending otherwise hasn’t moved the number, and somebody has to put the actual cause on the page.
